HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00266552

Risperidone or placebo for conduct concerns in children with intellectual disabilities

About this title

A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation

Read the official source — NCT00266552
Medication studyAges 5–12ADHD
The study in practice

Understand this study

Who was this study for?

Listed age limits: 5 years to 12 years.

Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study clarity

Study information

Study start dateNot clearly listed
Recruitment status
Completed
Enrollment listed in the registry
118
Sponsor
Janssen Pharmaceutica N.V., Belgium
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Not clearly listed
Age range
From 5 Years to 12 Years
Official registry ID
NCT00266552
Official title
Show the full official title

The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Locations not listed

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Janssen Pharmaceutica N.V., Belgium.

Did this study involve medication?

Yes. The study involved medication, including risperidone.

Who was this study for?

Listed age limits: 5 years to 12 years.

Want to explore more studies?

Explore studies